RecruitingNewly Diagnosed Multiple Myeloma

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Eligible age

18+ yrs

Accepts

All genders

Locations

24 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Sponsor: AstraZeneca

You may qualify if…

✓ 1. Participants must be 18 years or older, at the time of signing the ICF.
✓ 2. Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria.
✓ 3. Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio.
✓ 4. Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment.
✓ 5. Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd) as determined by the Investigator.
✓ 6. ECOG performance status Grade of 0 to 2.
✓ 7. Participant must have adequate organ and bone marrow function.

You may not qualify if…

✕ 1. Participant has active or prior CNS or meningeal involvement of MM.
✕ 2. Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating plasma cells), Waldenström macroglobulinemia, or POEMS syndrome.
✕ 3. Participant has significant neurological or psychiatric condition posing risk or impairing evaluation.
✕ 4. Participant has any other significant medical condition that increases unacceptable risk, interferes with therapy delivery, or confounds evaluation.
✕ 5. Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.
✕ 6. Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
✕ 7. Participant is positive for any of the following:
✕ 1. HIV: Known to be seropositive for HIV (including any history of HIV).